MiMedx Group, Inc (MDXG) traded with a cut of -0.04 points or -0.5% at $8.04 per share. As per the last available information, the stock aggregated $1.19 million in upticks and $0.05 million in downticks, keeping the net money flow capped at $1.14 million. The up/down ratio was found to be 23.52. For the week, the shares has seen a change of -0.12% in the share price.A block trade of $1.15 million in upticks and $0 million in downticks also took place during the day. The up/down ratio for the block stood at 0. The net money flow for this transaction was $1.15 million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
MiMedx Group, Inc. has lost 2.11% in the last five trading days and dropped 10.84% in the last 4 weeks. MiMedx Group, Inc. has dropped 11.34% during the last 3-month period . Year-to-Date the stock performance stands at -10.84%. MiMedx Group, Inc (NASDAQ:MDXG) witnessed a decline in the market cap on Wednesday as its shares dropped 2.23% or 0.18 points. After the session commenced at $8.13, the stock reached the higher end at $8.195 while it hit a low of $7.86. With the volume soaring to 829,052 shares, the last trade was called at $7.9. The company has a 52-week high of $10.02. The company has a market cap of $865 million and there are 109,514,557 shares in outstanding. The 52-week low of the share price is $6.64.
Company has reported several Insider transactions to the SEC, on Sep 8, 2016, William Charles Taylor (President and COO) sold 20,400 shares at 7.55 per share price.On May 23, 2016, Parker H Petit (CEO) purchased 20,000 shares at 6.99 per share price.On Nov 16, 2015, Charles Robert Evans (director) purchased 10,000 shares at 7.84 per share price.
MiMedx Group Inc Last issued its quarterly earnings results on Oct 27, 2016. The company reported $0.06 EPS for the quarter. Analyst had a consensus estimate of $0.06. The company had revenue of $64.40 million for the quarter, compared to analysts expectations of $63.12 million. The companys revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.MiMedx Group Inc was Initiated by UBS on Dec 12, 2016 to Sell, Price Target of the shares are set at $9.MiMedx Group Inc was Initiated by Aegis Capital to Buy on Nov 8, 2016.
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.